Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Protective Efficacy of a Synthetic Vaccine Derived From the CS Protein of Plasmodium Vivax: a Double-blind, Placebo-controlled, Randomized Clinical Trial in naïve and Pre-immune Colombian Volunteers

NCT04739917 is registered in ClinicalTrials.gov with Malaria Vaccine and Drug Development Center as lead sponsor.

NCT NCT04739917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04739917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Protective Efficacy of a Synthetic Vaccine Derived From the CS Protein of Plasmodium Vivax: a Double-blind, Placebo-controlled, Randomized Clinical Trial in naïve and Pre-immune Colombian Volunteers
Lead sponsor
Malaria Vaccine and Drug Development Center
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2021
Completion date
December 1, 2022
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, vivax